PHAT Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 7.7%, SMA50 -5.89%, SMA200 16.63%). The stock’s 14-day RSI is 54.76 (neutral), while the ATR of 0.94 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.94% below its high and over 513.57% above its low. Average 10-day trading volume of 1.26 million shares is in line with the 3-month average of 1.31 million, indicating normal recent market interest.

Phathom Pharmaceuticals, Inc. has 80.90 million shares outstanding. The public float is 65.29 million shares, elevated short interest at 17.34% of float. This equals 13.33 million shares. The short ratio is 9.31 days. Institutional investors hold 94.03% of the float. Insiders own 4.73%. TAKEDA PHARMACEUTICAL CO LTD holds 3.76 million shares, Socks David A has 1.21 million shares and Curran Terrie has 360.46 thousand shares.

Phathom Pharmaceuticals, Inc. generated EPS of -$3.81 over the past year. Five-year average earnings growth is 12.5%. The latest quarter delivered EPS of -$0.21. The next quarter is forecast at -$0.40. Next year's EPS is expected at -$21.16. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $18.00. The high target offers 218.63% upside. The low target suggests 120.59% downside. The mean target is $23.57. This offers 188.85% upside. Phathom Pharmaceuticals, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended July 30, 2026, missed forecasts by 250.0%. The prior quarter beat by 117.65%. Over the last six quarters, Apple has recorded several small beats. These include 0.94% in May 01, 2025.

Phathom Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.10. This means the shares are trading below this model’s fair value.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) closed at $8.16 USD, losing -$0.52 (-5.99%) from the previous close of $8.68. The stock is currently within 5% of its 52-week low $8.07 and $18.31. With a market capitalization of about $660.15 million, Phathom Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.51). Key stats such as the average daily volume over the past year has been around 1.31 million shares, in line with its 52-week average. Headquartered in Florham Park, NJ, Phathom Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven L. Basta, the company employs approximately 371 people and listed since October 25, 2019. Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments.

Our AI price prediction model suggests that Phathom Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.21%, with price expected at $8.34 by September 29, 2026, within a range of $7.47 to $9.30 3-Month Outlook: Projected fall of -20.1%, reaching $6.52 by December 11, 2026, with a range of $5.68 to $7.09. 1-Year Outlook: Projected loss of -67.4%, with price at $2.66 by September 15, 2027, within a range of $0.00 to $0.00.

Phathom Pharmaceuticals, Inc. trades at a P/E ratio of -6.34, slightly below the S&P 500 average, with a price-to-sales ratio of 2.74 and a price-to-book ratio of -1.98 indicating negative book value, which may reflect financial stress. The P/FCF stands at -17.9, also below market averages.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) shares are down -14.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Phathom Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -6.34. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $27.91, suggesting 242.03% upside. Our AI forecast model points to short-term strength (2.21% over two weeks), a medium-term fall (-20.1% over three months), and a longer-term loss (-67.4% over one year), with expected trading ranges indicating moderate volatility.